Status and phase
Conditions
Treatments
About
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM303 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, cervical cancer and other solid tumors (confirmed by histology) for which existing treatment is ineffective or without standard treatment;
The patient has residual lesions that can be used for surgical resection (>1.5cm3) or biopsy (>1.5cm3) and measurable after resection for TIL collection and efficacy evaluation;
Laboratory inspection index requirements:
Left ventricular ejection fraction (LVEF) ≥ 50%;
ECOG physical condition is 0 or 1;
The expected survival time is more than 3 months;
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Central trial contact
Feng e Li
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal